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doi:10.1016/j.kjms.2012.04.039Abstract We report the case of a 72-year-old woman with malignant melanoma and multiple
metastases; the largest tumor was in the ileum. The patient experienced general fatigue and
bloody feces for 1 month before consulting a nearby clinic. Blood tests revealed anemia, and
fecal occult blood was positive, but no abnormalities were detected using gastrointestinal
endoscopy and colonoscopy or the skin of the entire body. Computed tomography images of
the chest, abdomen, and pelvic region, and positron emission tomographyecomputed tomog-
raphy images of the entire body revealed multiple nodules in the ileum, left mammary gland,
left thyroid, right inguinal lymph node, and on the fascia of the right thoracic area and right
buttocks. The tumor in the left mammary gland was excised and immunohistochemical analysis
revealed that the excised tissue was positive for HMB45, melan-A, and MITF, but negative for
S-100 protein. Diagnosed with melanoma with multiple metastases, the patient underwent
four cycles of dacarbazine, nimustine hydrochloride, and vincristine (DAV) plus interferon beta
chemotherapy and one cycle of dacarbazine, nimustine hydrochloride, cisplatin, and tamox-
ifen (DAC-Tam) chemotherapy. Two series of embolizations of the artery feeding the ileum
tumors, as well as a series of plasma and red blood cell transfusions, were performed for ileum
tumor hemorrhage. The patient was hospitalized eight times, for a total of 204 days during the
1-year survival period before her death from respiratory failure.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.t of Geriatric and Environmental Dermatology, Graduate School of Medical Science, Nagoya City
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Malignant melanoma occurs in the small intestine either as
a primary mucosal tumor or as metastases from another
primary site, such as the skin, eyes, meninges, and anal
region. Most small intestinal malignant melanoma presents
as metastases [1]. Only a few have been reported as
a primary intestinal malignant melanoma in the strict sense
of the word [2].
Here, we report a case of malignant melanoma with
multiple metastases, with the ileum suspected to be the
primary site. Chemotherapy is the preferred treatment for
malignant melanoma with multiple metastases and we
administered dacarbazine, nimustine hydrochloride,
and vincristine (DAV) plus interferon beta chemotherapy
and dacarbazine, nimustine hydrochloride, cisplatin, and
tamoxifen (DAC-Tam) chemotherapy. The progress of the
patient and necessary treatments are discussed.Figure 1. Multiple nodules found by computed tomography (CT) w
(C) regions, and positron emission tomographyecomputed tomogr
correspond to the same nodules. Only PET-CT detected the nodu
detected on the skin of the entire body, in the orbital area, or the
a nodule in the ileum.Case report
A 72-year-old woman with a history of hysteromyotomy,
diabetes mellitus, and hypertension was referred to our
hospital for the treatment of malignant melanoma with
multiple metastases in October 2009. She had experienced
general fatigue and bloody feces and initially consulted
a nearby clinic in July 2009. Blood tests revealed anemia
with a hemoglobin level of 7.1 gm/dl. Occult fecal blood
was detected, but no abnormalities were detected using
gastrointestinal endoscopy and colonoscopy, including the
distal end of the ileum. She was referred to a gastroenter-
ologist at a general hospital during the following month.
Computed tomography with contrast medium of the
thorax, abdomen, and pelvic regions and positron emission
tomographyecomputed tomography images of the entire
body revealed multiple nodules in the ileum, left mammary
gland, left thyroid, right inguinal lymph node, and on theith contrast medium of the thorax (A), abdomen (B), and pelvic
aphy (PET-CT) images of the entire body (D). Circles and lines
le on the right thoracic area on the fascia. No lesions were
oral, genital, and anal mucosal areas. The largest tumor was
Figure 2. Excision biopsy of the nodule in the left mammary gland. Macroscopy of the nodule showed a dark black core (A, B).
Hematoxylin and eosin staining of the specimen revealed an intense concentration of melanin in the center and multiform cells
with distinct nucleoli and large nuclei surrounding the melanin-rich core of the tumor. The gross structure of this lesion consisted of
that of lymphatic follicles surrounded by lymphatic corpuscle, and much of them were replaced by these multiform cells (C, D).
[hematoxylin-eosin, original magnifications x20 (D), and x400 (D)].
Small intestinal melanoma of unknown origin 685fascia of the right thoracic area and right buttocks. The
largest tumor in the ileum was 3.5 cm by 3 cm in size in the
CT image slice. Among these nodules, there was also
a swelling of the mesenteric lymph node of the ileum
(Fig. 1).
Before the CT and PET imaging tests, no lesions were
detected on the skin of the whole body, the orbital area, or
the oral, genital, and anal mucosal areas. The largest tumor
was a nodule in the ileum. The only palpable nodule was
found in the left mammary gland area after the CT and PET
imaging test and an excision biopsy was performed on this
nodule. Macroscopy of the nodule showed a dark black core
(Figs. 2A and 2B). Hematoxylin and eosin staining of the
specimen revealed an intense concentration of melanin in
the center and multiform cells with distinct nucleoli and
large nuclei surrounding the melanin-rich core of the
tumor. The gross structure of this lesion consisted of that of
lymphatic follicles surrounded by lymphatic corpuscle, and
much of them were replaced by these multiform cells (Figs.
2C and 2D). Immunohistochemical analysis revealed that
the excised tissue was positive for the melanocyte markers
HMB45, melan-A, and MITF, but negative for S-100 protein.
The pathologic diagnosis was metastatic malignant mela-
noma to a lymph node of the left mammary gland area. The
patient was referred to the Department of Dermatology of
our hospital in October 2009, because, despite the absence
of a skin lesion, dermatologists in this region have the most
experience in treating malignant melanoma.
Laboratory testing revealed a white blood cell count of
8.0 x 103/ml (neutrophils 73.0%, lymphocytes 22.0%,monocytes 3.0%, eosinophils 2.0%, basophils 0.0%), hemo-
globin 7.6 g/dl, and hematocrit 27.7%. Mean corpuscular
volume and mean corpuscular hemoglobin were within
normal limits, but mean corpuscular hemoglobin concen-
tration was only 27.4%, indicating normocytic anemia.
Blood chemistry revealed hypoproteinemia (6.0 g/dl),
hypoalbuminemia (3.5 g/dl), low blood ferritin (15 mg/dl),
low unsaturated iron-binding capacity (304 mg/dl), and
elevated serum 5-S-cysteinyldopa (5-S-CD) levels (59.4
nmol/l). The electrolyte levels and urinalysis results were
within normal limits. Bone scintigraphy revealed no space-
occupying lesions in the bones of the entire body.
We diagnosed the patient with malignant melanoma
stage IV of unknown origin, with the ileum suspected to be
the primary site, and multiple organ metastases to the left
mammary gland, left thyroid, right inguinal lymph node,
and on the fascia of the right thoracic area and right
buttocks. We explained to the patient that chemotherapy,
but not surgery, might improve the prognosis. She elected
to undergo chemotherapy.
The entire course of treatment from her first visit to our
department to her death 1 year later is shown in Fig. 3.
Four cycles of DAV plus interferon beta chemotherapy and
one cycle of DAC-Tam (dacarbazine, nimustine hydrochlo-
ride, cisplatin, and tamoxifen) chemotherapy were
administered during the 1-year treatment period. Although
the tumors continued to shrink and serum 5-S-CD levels
remained low for the first three cycles of DAV plus inter-
feron beta chemotherapy, the fourth cycle was not effec-
tive as we observed an increase in the tumor size, further
686 S. Suzuki et al.metastases in the liver and brain, and an increase in serum
5-S-CD levels (Figs. 3 and 4). We then changed the
chemotherapy regimen to DAC-Tam and the serum 5-S-CD
levels initially decreased, but began to increase again 1
month later. Scintigraphy with 99mTc-labeled red blood
cells revealed bleeding from the tumor in the ileum. Two
series of embolizations of the artery feeding the ileum
tumors, as well as a series of plasma and red blood cell
transfusions, were performed when the hemoglobin level
dropped. In the 11th and 12th months, a nasogastric tube
for suction and parenteral nutrition were introduced due to
ileus, which resolved within a few days each time. She was
admitted to our hospital eight times for a total of 204 days
and spent 150 days at home during the 1-year period.
Throughout the course, we did not find any skin lesions both
by anthroposcopy and by imaging technique with CT and
MRI. She died of respiratory failure due to metastasis to the
lung 1 year after her first visit to us.
Discussion
Malignant melanoma of the small intestine can occur either
as a primary tumor or as metastases of cutaneous, ocular,
or anal melanomas [1]. The majority of melanomas occur as
metastases from primary cutaneous lesions and necropsyFigure 3. The entire course of treatment. Four cycles of DAV
plus interferon beta chemotherapy and one cycle of DAC-Tam
chemotherapy were administered. The size of the tumors
continued to shrink for the first three cycles of DAV, plus
interferon beta chemotherapy and serum 5-S-CD levels
remained low, which is indicated by the blue line. The fourth
cycle of DAV plus interferon was not effective, as we observed
an increase in the tumor size, further metastases in the liver
and brain, and an increase in serum 5-S-CD levels. We then
changed the chemotherapy regimen to DAC-Tam and the serum
5-S-CD levels initially decreased, but began to increase again 1
month later. Scintigraphy with 99mTc-labeled red blood cells
revealed bleeding from the tumor in the ileum. Two series of
embolizations of the artery feeding the ileum tumors, as well
as a series of plasma and red blood cell transfusions, were
performed when the hemoglobin level dropped, as indicated by
the orange line. She was admitted to our hospital eight times
for a total of 204 days and spent 150 days at home. She died of
respiratory failure due to metastasis to the lung 1 year after
the first visit to us.studies indicate that 58% of patients with malignant mela-
noma have lesions in the small intestine, in contrast to 26%
with stomach cancer, and 28% with colon cancer. Thus,
malignant melanoma tends to metastasize to the small
intestine more often than other common gastrointestinal
malignancies [3], but only 1.5% to 4.44% of these are clin-
ically diagnosed before death [1].
Primary small intestinal melanoma, on the other
hand, is also rare. Only 2% of all melanoma occurs as
the primary site in the small intestine [1]. If primary
melanoma of the small intestine is defined as (1) biopsy-
proven melanoma from the small intestine at a single
focus; (2) no evidence of disease in any other organs,
including the skin, eye, and lymph nodes outside the
regional drainage at the time of diagnosis; and (3)
disease-free survival of at least 12 months after diag-
nosis, as suggested by Sachs et al., only a few cases
have been reported to date [2]. Melanocytes are neural
crest-derived cells that migrate via the mesenchyme
into the epidermis, dermis, hair follicles, peripheral
nerves, around the blood vessels, eye (choroid, ciliary
body, and iris), leptomeninges, and inner ear (cochlea).
It may migrate embryologically along outgrowing sensory
nerves and deposit in the intestine [2,4].
Our patient had multiple nodules in the ileum, left
mammary gland, left thyroid, right inguinal lymph node,
and on the fascia of the right thoracic area and right
buttocks, with the largest tumor in the ileum. Considering
the potential locations of melanocytes described above and
the size of each nodule, the ileum was suspected to be the
primary site of the malignant melanoma in the present
case. If this is the case, the swelling of the mesenteric
lymph node of the ileum detected by CT images might have
been the metastasis from the ileum. Since the right inguinal
lymph node was also suspected be the metastatic mela-
noma, there might have been primary cutaneous melanoma
of the right leg or foot and the skin lesion might have
regressed spontaneously. We looked carefully to see if
there was a scar, which might be the sign of regressed
melanoma, but there was no skin lesion in this area. It is not
possible to prove these assumptions and the present case
was treated as melanoma of an unknown primary site. In
the diagnosis of metastatic melanoma, immunohistochem-
ical stains are useful [5]. S-100, HMB-45, melan-A, and MITF
are positive in malignant melanoma [5-7]. The present case
was negative for S-100, which occurs in 8.5% of all malig-
nant melanoma [6].
It is difficult to improve the prognosis of malignant
melanoma in the small intestine without complete resec-
tion [1]. The present case had multiple metastases at the
initial visit, which made it impossible to perform
a complete resection, and chemotherapy was the choice
of therapy. DAV plus interferon beta chemotherapy was
retrospectively examined by Nagatani et al. The 5-year
survival rate of patients with stage III (N2) and IV disease
treated with DAV plus interferon beta chemotherapy is
13% [8]. The present case reacted well to this chemo-
therapy for the first three cycles, as the serum 5-S-CD
levels remained low and the size of the tumors decreased
on CT images. Measuring serum 5-S-CD levels in stage
IV patients is advantageous in assessing the state of
melanoma, since the substance is related to melanin
Figure 4. Change in the size and distribution of the tumors, taken as CT images (A-H) and an MRI image (I). The size of the tumors
in the ileum (A) and in the right inguinal lymph node (E) before the start of chemotherapy was reduced during the first three cycles
of DAV plus interferon chemotherapy (B, F). The tumors grew in size after the fourth cycle of DAV plus interferon chemotherapy
(C, G), and after subsequent DAC-Tam chemotherapy (D). Pleural effusion with metastasis to the lung (H) and metastases to the
brain (I) were clear at this point.
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feron beta chemotherapy, however, both the serum 5-S-
CD levels and the size of the tumors in CT images began to
increase, and we changed the chemotherapy regimen to
DAC-Tam, a modification of the Dartmouth regimen,consisting of carmustine, dacarbazine, cisplatin, and
tamoxifen [10].
In a prospective study by Yamazaki et al., 40% of
patients with stage IV malignant melanoma had a more
than 50% reduction in tumor size for at least 4 weeks after
688 S. Suzuki et al.DAC-Tam chemotherapy [11]. In the present case, the
serum 5-S-CD levels initially decreased, but began to
increase again 1 month after DAC-Tam chemotherapy. The
size of the tumors in CT images increased even after DAC-
Tam chemotherapy. A case in which a series of DAV plus
interferon beta chemotherapy was applied and became
ineffective at the later stage, DAC-Tam chemotherapy,
which might have a better chance of being effective to
stage IV cases, is also of a limited therapeutic effect. An
accumulation of such case studies is needed to clarify the
effect of these chemotherapies.
Clinical presentation of small intestinal malignant
melanoma includes intestinal intussusception, ileus,
hematemesis, bloody feces, melena, and perforation [1].
The present case required two series of embolizations of
the artery feeding the ileum tumor, together with a series
of plasma and red blood cell transfusions when the
hemoglobin level dropped. To treat ileus, which occurred
in the 11th and 12th months, a nasogastric tube for suction
and parenteral nutrition were introduced for a few days
each time. At least three hospital admissions, for 60 days
in total, were for the purpose of treating bleeding from
the ileum tumor and anemia. Although operative resection
of the ileum tumor would not have improved the prog-
nosis, it may have improved the quality of this patient’s
life before death. To present the treatment choices with
an accurate prognosis, a case report such as the present
one becomes important. As the number of malignant
melanoma cases increases, cases of noncutaneous malig-
nant melanoma will also increase. Dermatologists also may
be consulted for treatment of noncutaneous malignant
melanoma. Therefore, a clear understanding of such
tumors is necessary.References
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